Transforming catheter placement
28 January, 2014A new tool that guides catheter placement is being taken up by Australian hospitals.
Starpharma starts human trial of DEP-docetaxel
24 January, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has received the approvals required to kick off the first human trial of dendrimer-enhanced chemotherapy formulation DEP-docetaxel.
Op-shopping the genome yields RNA gold
22 January, 2014 by Fiona WylieShakespeare’s Hamlet was correct - "what a piece of work is a [hu]man! ... how infinite in faculty" - and now it seems, according to a team of researchers in Sydney, in gene expression regulation.
Patrys's SC1 boosts 10-year survival in gastric cancer
22 January, 2014 by Dylan Bushell-EmblingLong-term follow-up data from a trial of Patrys's (ASX:PAB) IgM antibody PAT-SC1 in gastric cancer shows improved 10-year survival rates in treated patients.
Imugene adds to scientific board
21 January, 2014 by Dylan Bushell-EmblingImugene has appointed to its scientific advisory board two Austrian scientists who were instrumental in the development of the company's cancer vaccine candidate HER-Vaxx.
Abraxane improves survival in pancreatic cancer trial
21 January, 2014 by Dylan Bushell-EmblingAbraxane, a chemotherapy drug licensed in Australia by STA, achieved a three-year overall survival of 4% during a combination trial in metastatic pancreatic cancer.
Prima gets first approval for CAN-004 trial
20 January, 2014 by Dylan Bushell-EmblingBelgium's FAMHP has become the first regulator to sign off on the modified protocol for Prima BioMed's (ASX:PRR) upcoming trial of CVac in ovarian cancer.
New diagnostic test for coeliac disease
20 January, 2014A new blood test that can produce results within 24 hours may provide a simpler and less invasive test for detecting coeliac disease.
Protein blocks escape route for cancer cells
17 January, 2014A protein that can potentially block the spread of cancerous cells is providing new insights into cancer biology.
Patrys raises $1.3m through shortfall issue
17 January, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has raised $1.3m through a share placement and is working with the managers of last month's rights issue to place more of the shortfall shares.
Benitec cleared for first-in-[hu]man hep C trial
15 January, 2014 by Dylan Bushell-EmblingThe US FDA has given Benitec Biopharma (ASX:BLT) approval to conduct a first-in-[hu]man trial of ddRNAi-based hepatitis C treatment candidate TT-034.
Potential new target for halting cancer growth
15 January, 2014Blocking a specific protein that drives the rapid growth of cancer cells could provide a promising strategy for treating cancers that express high levels of the transcription factor MYC.
Starpharma expects $4.7m R&D tax rebate
15 January, 2014 by Dylan Bushell-EmblingFollowing a positive AusIndustry decision on overseas R&D, Starpharma (ASX:SPL) expects to receive a $4.7 million rebate this financial year for development work conducted during FY13.
STA to distribute breast cancer test in Australia
14 January, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has clinched a deal to become the Australian distributor for Oncotype DX, a genomic test used to inform treatment strategies for breast cancer patients.
Viralytics hits recruitment target for cancer trial
09 January, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has reached its 54-patient recruitment target for a US phase II trial of its Cavatak cancer treatment in malignant late-stage melanoma.
